Acer Therapeutics — Opexa Therapeutics — Investor Presentation (October 2014)
37 slides from Acer Therapeutics's investor presentation, Oct 9, 2014
Slide 1: Opexa Therapeutics: Precision Immunotherapy
Ex Opexa Therapeutics, Inc. Opexa Therapeutics, Inc. NASDAQ: OPXA Precision Immunotherapy October 2014 The Woodlands, TX Precision Immunotherapy (R)
Slide 2: Forward-Looking Statements
Forward-Looking Statements All statements in this presentation other than those of historical fact, including statements regarding our preclinical and clinical development plans for Tcelna (R) and OPX-212, our research and other development programs, our ability to undertake certain activities and a
Slide 3: Opexa Key Investment Highlights
Opexa Key Investment Highlights Personalized T-cell immunotherapy platform –Autologous cell therapy –Potential to address multiple therapeutic areas –Strong Patent Estate: 98 patents issued on T-cell platform (domestic and international) Lead Indication: Multiple Sclerosis –Ongoing Phase 2b trial in
Slide 4: Opexa: A Unique Drug Discovery Engine
Opexa: A Unique Drug Discovery Engine Personalized, targeted immune therapies Potential new autoimmune indications e.g. Type 1 Diabetes Lupus Myasthenia Gravis Several orphan diseases Secondary Progressive Multiple Sclerosis Neuromyelitis optica Strong IP Estate ImmPath®: Opexa’s Proprietary Platfor
Slide 5: Developing Highly Differentiated, Precision Therapies
Opexa Developing Highly Differentiated, Precision Therapies OPX-212 Preclinical Phase 1 Phase 2 Phase 3 Programs and indications Neuromyelitis Optica (NMO) IND enabling activities ongoing in 2H 2014 Tcelna (imilecleucel-T) * Relapsing Remitting Multiple Sclerosis (RRMS) Phase 3 not initiated *Option
Slide 6: Recent and Upcoming Expected Milestones
Recent and Upcoming Expected Milestones Tcelna: Multiple Sclerosis 1H 2014: Completed Enrollment in Phase 2b SPMS trial 2H 2016: Top line results for Abili-T Phase 2b SPMS trial OPX-212: NMO 1H 2014: Initiated Early Development Plan Mid- 2015: Submit IND 2H 2015: Initiation of Clinical Development
Slide 7: Financials
Financials Cash and Cash Equivalents (MM) as of June 30, 2014 $16.2 Shares outstanding (MM) as of June 30, 2014 ~27.7 Warrants (MM) (1) ~3.1 Stock Options (MM) (2) ~2.5 Debt None (1)Weighted average exercise price =$4.12 as of June 30, 2014 (2)Weighted average exercise price = $2.96 as of June 30, 2
Slide 8: Tcelna Multiple Sclerosis
TCELNA® MULTIPLE SCLEROSIS TCELNA® (imilecleucel-T) MULTIPLE SCLEROSIS
Slide 9: Tcelna Lead Program Targeting Secondary Progressive MS
Tcelna® Lead Program Targeting Secondary Progressive MS patients Fast Track Designation by FDA Phase 2b clinical trial ongoing Trial is fully enrolled: 190 patients with SPMS Top line data expected in 2H 2016 Design –Double-blind, 1:1 randomized, placebo-controlled –35 clinical sites in USA and Cana
Slide 10: The Root Cause of Multiple Sclerosis: Activated T-cells
The Root Cause of Multiple Sclerosis: Activated T- cells Degrade Myelin and Damage Myelin Producing Cells Adapted by permission from Macmillan Publishers Ltd: NATURE REVIEWS IMMUNOLOGY 3, 483-492 (June 2003), copyright (2003) Cytokines Damage Damage In MS patients, the faulty immune system is not ab
Slide 11: Differentiation of Tcelna in SPMS
Differentiation of Tcelna in SPMS SPMS $7 billion ? RRMS $13 billion ? Tcelna * glatiramer acetate Novantrone Blood Brain Barrier sealed natalizumab Beta interferon teriflunomide X Safe and well tolerated siponimod * Subject to successful clinical development and FDA approval X Lack of efficacy demo
Slide 12: Merck Serono Agreement
Merck Serono Agreement signed 2013; strong potential partner Option and License Agreement for worldwide rights to all Multiple Sclerosis indications, excluding Japan If Merck Serono exercises option: –Merck Serono to fund Phase 3, pre-commercial and commercial activities –Merck Serono obtains rights
Slide 13: Clinical Data: Multiple Sclerosis
CLINICAL DATA: MULTIPLE SCLEROSIS CLINICAL DATA: MULTIPLE SCLEROSIS
Slide 14: Tcelna Development Program
Tcelna Development Program Broad Spectrum of Multiple Sclerosis patients enrolled in clinical trials Phase Completion Dates Population Total N Treatment Duration (months) Tcelna Placebo Baylor 1998 RRMS, PPMS, SPMS (26) 114 Up to 24 months 114 Phase I dose escalation 2006 RRMS (5) SPMS (6) 16 12 16
Slide 15: Mechanism of Action
Mechanism of Action Reduction in Myelin Reactive T-Cells -100%-90%-80%-70%-60%-50%-40%-30%-20%-10%0%Week 0Week 5Week 13Week 21Week 28Week 52Results from Tcelna dose ranging studies: Published in Clinical Immunology (2009) 131, 202-215 Reduction in MRTC Dose 2 Dose 3 Dose 4 Each dose consisting of 30
Slide 16: Phase 2b RRMS Trial: 37% Improvement Over Placebo
Phase 2b RRMS clinical trial Tcelna showed 37% improvement over placebo (mITT) 0.214 0.339 00.050.10.150.20.250.30.350.437% Reduction in Annualized Relapse Rate (ARR) 37% Reduction in Annualized Relapse Rate (ARR)TcelnaPlacebon=94 n=48 Relapses/Patient/Year 37% Total mITT population
Slide 17: Phase 2b RRMS: Reversal of Disability in More Active Patients
Phase 2b RRMS Clinical Trial Reversal of Disability in Prospective Analysis in More Active Patients Sub-population of patients (n=50) with more progressed/active disease profile (baseline ARR >1) 2.4 2.23 2.2 2.39 2.102.152.202.252.302.352.402.45EDSS Score (Mean) BASELINE WEEK 52 TcelnaPlacebo(p=0.0
Slide 18: Phase I/II SPMS: Tcelna Stabilizes Disease at 2 Years
Phase I/II SPMS Clinical Trials Tcelna Stabilizes Disease in SPMS at 2 Years 80% 20% 40% 0%20%40%60%80%100%Percent of Patients Showing Disease Stabilization Stabilization vs. Historical Progression Stabilization vs. Historical Progression StableProgressed80% of patients showed no further disease pro
Slide 19: ImmPath: Proprietary Drug Development Platform
IMMPATH® : PROPRIETARY DRUG DEVELOPMENT PLATFORM IMMPATH® : PROPRIETARY DRUG DEVELOPMENT PLATFORM
Slide 20: Proprietary Platform
Proprietary Platform Leverage existing platform to generate new drug candidates ImmPath® Manufacturing Process Predecessors to Manufacturing Manufacturing Dispensation Epitope Shipment of blood to Opexa Profiling Specimen logged and assigned a performed unique identifier number to define patient spe
Slide 21: Strengths and Advantages of Opexa Platform
Strengths and Advantages of Opexa Platform Potential Reduced Time and Cost to First in Man Study ImmPath, Opexa proprietary platform –Advantages: Possibility exists to generate multiple drug candidates Potential reduction in time to market Potential reduction in development cost Preclinical timeline
Slide 22: OPX-212: Neuromyelitis Optica (NMO)
OPX-212: NEUROMYELITIS OPTICA (NMO) OPX-212: NEUROMYELITIS OPTICA (NMO)
Slide 23: Process to Determine Optimal Additional Indications
Comprehensive Process to Determine Optimal Additional Indications for Opexa Addison’s disease Autoimmune hemolytic anemia Celiac Disease Goodpasture’s syndrome Grave’s Disease Hashimoto’s thyroiditis Idiotypic thrombocytopenic purpura Myasthenia Gravis Neuromyelitis Optica (NMO) Pemphigus vulgaris/f
Slide 24: NMO: A Rare Disease of the Central Nervous System
NMO: A rare disease of the Central Nervous System Neuromyelitis optica (NMO) is a rare or orphan autoimmune disease Immune system cells and antibodies mistakenly attack and destroy myelin cells in the optic nerves and the spinal cord Individuals with NMO develop optic neuritis, which causes pain in
Slide 25: Disease Pathogenesis
Disease Pathogenesis An astrocytopathic disease of the CNS characterized by optic neuritis, transverse myelitis; it is a B-cell-dependent disease associated with anti-aquaporin-4 antibodies NMO Pathogenic T-Cells Anti-AQP-4 Plasma Cell Binding to AQP4 channels on the astrocytes Increase astrocyte pe
Slide 26: Potential Intervention Points for T-cell Therapy
Potential Intervention Points for T-cell Therapy T-cell therapy believed to inhibit AQP-4 autoantibody, pro-inflammatory cytokines and prevent infiltration of macrophages and granulocytes Without the pathogenic T-cell, the B-cell does not signal the production of the AQP-4 antibody Possible results:
Slide 27: Current Therapeutic Approach vs OPX-212
Current therapeutic approach Systemic immunosuppression can lead to infections and cancers. Long term consequences not understood Fails to re-educate the immune response for immune ‘tolerance’ to AQP-4 NMO Potential to avoid systemic immunosuppression Potential to selectively decrease AQP-4 reactive
Slide 28: Orphan Drug Model: Substantial Regulatory Advantages
Orphan Drug Model: Substantial Regulatory Advantages 0246Non-orphanOrphanPhase II to launch clinical development time Years84%86%88%90%92%94%Non-orphanOrphanProbability of regulatory success * Rare diseases, also known as orphan diseases, individually affect small groups of patients but are estimate
Slide 29: Orphan Drug Model: Significant Economic and Commercial Potential
Orphan Drug Model: Significant Economic and Commercial Potential Market exclusivity for orphan designated drugs: - U.S. 7 years; EU 10 years Orphan Drug Strategy Tax Credits R & D Grants Shorter Development Timelines Greater Regulatory Success Premium Pricing Faster Uptake Longer Exclusivity Lower H
Slide 30: NMO Development Program
NMO Development Program OPX-212 Early Development Plan was initiated in Q1 2014 Planned Development Activities 2014 Preclinical Development Mid-2015 IND submission (subject to successful preclinical development) 2H 2015 Clinical Development (subject to FDA review and acceptance of IND) Completed Act
Slide 31: NMO Early Development Program
NMO Early Development Program Activities to support IND submission; Process and Product Development NMO patient apheresis samples are being utilized to help develop the Epitope Profile Assay to define T-cell reactivity to AQP4, as well as to refine the manufacturing process for OPX-212, and executin
Slide 32: OPX-212: Potential US Product Launch
OPX-212: Potential US product launch projected as early as 2021 Submit IND BLA filing U.S. Approval & Launch Clinical Development Program * Orphan Drug Designation Fast Track Designation 2019 2017 2021 2018 2022 2020 2016 2015 Phase I/II Proof-of-Concept Trial Phase III Registrational Trial Phase 1/
Slide 33: Global Patient Breakdown in 2021
Global Patient Breakdown in 2021 North America: EU:19% Global patient numbers estimated at 70,000 – 140,000 Japan 11% China 51%
Slide 34: NMO Investment Thesis
NMO Investment Thesis Any therapy that could achieve tolerization of the AQP-4 reactive T-cells may offer a cure for NMO OPX-212 has the potential to address the root cause of NMO OPX-212 leverages Opexa’s T-cell platform to B-cell mediated orphan diseases Opexa retains world wide economics from OPX
Slide 35: Experienced Management Team and Board of Directors
Experienced Management Team and Board of Directors Neil Warma, President & CEO, Director 19+ years international healthcare experience with large Pharma and emerging biotechnology companies Former Senior Management, Novartis Pharmaceuticals, Basel, Switzerland Former CEO, Viron Therapeutics, Inc. Co
Slide 36: SPMS Scientific Advisory Board
SPMS Scientific Advisory Board Dawn McGuire, M.D., FAAN (Chair) Advisory Council of the Gill Heart Institute Former Vice President of Clinical Research at Elan Pharmaceuticals Hans-Peter Hartung, M.D Chair of Neurology at Heinrich-Heine University, Düsseldorf Executive Board member of ECTRIMS, World
Slide 37: Opexa Investment Thesis
Opexa Investment Thesis PIPELINE Tcelna: Secondary Progressive MS, limited competition, $7BN potential market OPX-212: Recently launched development program in NMO, no approved therapies, orphan indication Precision Immunotherapy potentially optimizes benefit-risk profile VALIDATION Option agreement
Opexa Therapeutics — Investor Presentation (October 2014) on 6ix